Based: Newark, CA
Investors: Accuitive Medical Ventures, Carlyle Group, Essex Woodlands Health Ventures, MPM Capital, SV Life Sciences Advisers, and Versant Ventures
Scoop: NeoVista received backing for its efforts in the macular degeneration field from several previous investors. The new Series E round, valued at $33 million, was announced in February.
NeoVista's approach to macular degeneration differs from the norm, where injectables reign. Instead, the company uses an intraocular brachytherapy device, administering radiation to the choroidal vascular bed of the retina. The procedure has undergone three clinical trials, including one 500-patient Phase III trial, with some results still pending.